BYOMass Inc

2:00 PM - 2:15 PM (EDT), Monday, June 5, 2023 ・ Session Room 104C
BYOMass is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily, for the treatment of orphan and common diseases of high unmet medical need. Our mission is to:
*Harness human biology
*Target causative mechanisms
*Deliver novel therapeutics
*Transform patient lives
BYOMass is pioneering a precision medicine approach to treat patients where dysregulation of specific superfamily members play a major role in their disease. Our approach to building a therapeutic pipeline follows these principles:
*Efficacy: Harnessing human biology and causal mechanisms of disease for transformative efficacy
*Avoiding known toxicities associated with directly blocking TGF-β or subfamily receptors
*Preclinical to Clinical Translation: Utilizing plasma biomarkers to stratify patients and build confidence in human dose
*Building candidates to survive: High confidence in PK/PD and therapeutic index to test MOA in p
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Multiple Therapeutics
Lead Product in Development:
Anti-GDF-15 and Anti-Activin A mAbs
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):